Ibrahim Turkoz, MS

Response to Esketamine After Initial Nonresponse

July 20, 2021

Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate...

Ibrahim Turkoz , Ella Daly , Jaskaran Singh , et al

Original Research

Half-Life After Antipsychotic Discontinuation

August 23, 2017

Read the results on whether a longer half-life is associated with longer time to relapse after antipsychotic discontinuation, even among LAI formulations.

Peter J. Weiden , Edward Kim , Jason Bermak , et al

Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

Dong-Jing Fu , Ibrahim Turkoz , R. Bruce Simonson , et al

Letter to the Editor

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

October 15, 2012

Larry Alphs , William H. Olson , Ibrahim Turkoz , et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

May 15, 2010

Carla M. Canuso , Jean-Pierre Lindenmayer , Colette Kosik-Gonzalez , et al

Original Research

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

August 15, 2006

George M. Simpson , Ramy A. Mahmoud , Robert A. Lasser , et al

Letter to the Editor

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

January 16, 2006

Georges M. Gharabawi , Cynthia A. Bossie , Ramy Mahmoud , et al

Original Research

Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder

February 15, 2005

Jaspreet S. Brar , Rohan Ganguli , Gahan Pandina , et al

Original Research

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

March 1, 2004

Glenn W. Currier , James C-Y Chou , David Feifel , et al

Response to Esketamine After Initial Nonresponse

Half-Life After Antipsychotic Discontinuation

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

ELSEWHERE:

FOLLOW US:

Ibrahim Turkoz, MS

Response to Esketamine After Initial Nonresponse

Half-Life After Antipsychotic Discontinuation

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles